Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Prices $2.2B in Senior Notes

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has priced three series of senior notes totaling $2.2 billion in aggregate.

The firm is offering $300 million aggregate principal amount of 2.05 percent senior notes due 2014; $900 million aggregate principal amount of 3.2 percent senior notes due 2016; and $1 billion aggregate principal amount of 4.5 percent senior notes due 2021.

It expects to close the offering on Feb. 22, and said that the notes will pay interest on a semi-annual basis.

Thermo Fisher will use the proceeds to pay for its $2.1 billion acquisition of Dionex, which was announced in December.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.